WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Amgen

AmgenAmgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

www.amgen.com

Amgen RSS Channel

Filters
List of articles in category Amgen
Title Published Date
Amgen Golden Ticket winners receive lab space and other benefits at QB3@953 22 June 2016
Amgen and UCB announce positive top-line tesults from phase 3 study evaluating romosozumab In men with osteoporosis 21 March 2016
Amgen reacquires all product rights to Prolia® (denosumab), XGEVA® (denosumab) and Vectibix® (panitumumab) from GSK in 48 countries 15 December 2015
FDA approves IMLYGICTM (talimogene laherparepvec) as first oncolytic viral therapy in the US 28 October 2015
Amgen to acquire privately-held Dezima Pharma 16 September 2015
Amgen and Xencor announce strategic collaboration in cancer immunotherapy and inflammation 16 September 2015
European Commission approves Amgen's new cholesterol-lowering medication Repatha™ (evolocumab) 23 July 2015
Amgen announces collaboration with Roche on cancer immunotherapy study with investigational medicines talimogene laherparepvec and atezolizumab 02 June 2015
Amgen receives FDA Breakthrough Therapy Designation for investigational BiTE® antibody blinatumomab in acute lymphoblastic leukemia 01 July 2014
Amgen and Merck announce collaboration To evaluate investigational combination treatment for advanced melanoma 05 February 2014
Amgen Foundation commits $2.5 million in new grants to engage 50,000 students each year in the thrill of scientific inquiry 07 November 2013
Amgen's third quarter 2013 revenues increased 10 percent 24 October 2013
Amgen acquires Filgrastim franchise rights from Roche In 100 markets 22 October 2013
Amgen successfully completes Onyx Pharmaceuticals tender offer 02 October 2013
Amgen and ShanghaiTech University announce plans for Amgen China R&D center 25 September 2013
Amgen to acquire Onyx Pharmaceuticals for $125 per share in cash 26 August 2013
FDA approves Amgen's XGEVA® (denosumab) for the treatment of giant cell tumor of bone 16 June 2013
Amgen and Astellas announce Japan Alliance 29 May 2013
Amgen and Zhejiang Beta Pharma announce planned joint venture in China 10 May 2013
Amgen announces top-line results of phase 3 talimogene laherparepvec trial in melanoma 20 March 2013
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next
  • End

Business & Industry

  • Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare hematology
  • Roche's subcutaneous formulation of Tecentriq demonstrates positive Phase III results
  • Bayer Consumer Health leaders propose new principles for science-led self-care
  • GSK signs agreement to support pandemic preparedness in Europe
  • Pfizer and BioNTech advance COVID-19 vaccine strategy with study start of next-generation vaccine candidate based on enhanced spike protein design

Research & Development

  • Scientists create long-acting injectable drug delivery system for tuberculosis
  • Treating cancer by sticking cells in place
  • Vitamin K prevents cell death: a new function for a long-known molecule
  • Disparities in United States COVID-19 vaccine distribution
  • New needle-free nasal vaccine shows promise for COVID-19
  • Scientists develop new biomimetic formulation for treating glioblastoma
  • SARS-CoV-2 hijacks nanotubes between neurons to infect them

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Amgen

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.